[Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Current perspectives on EHEC, complement mutations and ADAMTS13].
Karpman
Diana
D
Avdelning för pediatrik, Lunds universitet. diana.karpman@med.lu.se
D051722:ADAM Proteins / Q000097:blood* / Q000172:deficiency / Q000235:genetics / Q000276:immunology; D000071120:ADAMTS13 Protein; D015415:Biomarkers / Q000097:blood*; D003165:Complement System Proteins / Q000235:genetics; D003937:Diagnosis, Differential; D054324:Enterohemorrhagic Escherichia coli / Q000472:pathogenicity; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D006801:Humans; D007672:Kidney Cortex / Q000473:pathology; D009154:Mutation; D011697:Purpura, Thrombotic Thrombocytopenic / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D012008:Recurrence; D013927:Thrombosis / Q000175:diagnosis / Q000209:etiology
D015415:Biomarkers; D003165:Complement System Proteins; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human